

## 2024 New Working Committee Studies

Working Committee	Study #	Study Title	Principal Investigators
Acute Leukemia	LK24-01	Sequencing of chimeric antigen receptor T-cell therapy and allogeneic transplantation in adult patients with B-cell acute lymphoblastic leukemia.	Donna Eng/ Joshua Fein/ Alexandra Arteaga/ Luis Gonzalez Mosquera/ Kitsada Wudhikarn/ Muhammad Bilal Abid/ Abu-Sayeeef Mirza
Chronic Leukemia	CK24-01	Identifying the optimal stem cell dosing for peripheral blood stem cell transplantation with post-transplant cyclophosphamide.	Hany Elmariah/ Arpita Gandhi/ Neli Bejanyan/ Richard Marziarz
Chronic Leukemia	CK24-02	Outcomes of allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid dysplastic syndrome and acute myeloid leukemia.	Ryan Stubbins/ Eric Wong/ Lucy Fox/ Lohith Gowda/ Stuart Seropian
Chronic Leukemia	CK24-03	Comparison of reduced intensity conditioning regimens for haploidentical donor hematopoietic cell transplant with post-transplant cyclophosphamide in patients with acute myeloid leukemia or myelodysplastic syndromes.	Hany Elmariah/ Shukaib Arslan/ Monzr Al Malki/ Neli Bejanyan
Chronic Leukemia	CK24-04	Comparison of post-transplant cyclophosphamide-based reduced intensity conditioning regimens for older patients with acute myelogenous leukemia and MDS.	Lizamarie Bachier/ Scott Solomon
Donor and Recipient Health Services	DHS24-01	Outcomes for medicaid beneficiaries following allogeneic hematopoietic cell transplantation: Exploring the impact of variable medicaid eligibility criteria.	Patrick DeMartino/ Navneet Majail
Graft-versus-Host Disease	GV24-01	Post-transplantation cyclophosphamide (PTCy)/sirolimus versus PTCy/calcineurin-inhibitor-based graft-versus-host disease prophylaxis.	Rohtesh Mehta/ Nelli Bejanyan
Graft-versus-Host Disease	GV24-02	Effect of acute graft-versus-host disease on the outcome of hematopoietic cell transplantation with post-transplantation cyclophosphamide: a CIBMTR analysis.	Ashley Hadjis/ Shannon McCurdy
Graft-versus-Host Disease	GV24-03	Differences in the characteristics of acute and chronic graft-versus-host disease after post-transplantation cyclophosphamide versus conventional calcineurin inhibitor-based graft-versus-host disease prophylaxis.	Rohtesh Mehta/ Rima Saliba
Immunobiology	IB24-01	6-locus HLA immunopeptidome divergence and outcome of mismatched unrelated HCT.	Esteban Arrieta-Bolaños/ Katharina Fleischhauer

## 2024 New Working Committee Studies

Working Committee	Study #	Study Title	Principal Investigators
Immunobiology	IB24-02	Effect of donor KIR and donor KIR ligand on CD8+ T cell-mediated alloreactivity in unrelated HSCT for AML, ALL and MDS.	Becca Asquith
Infection and Immune Reconstitution	IN24-01	Evaluating infection rates in autologous hematopoietic stem cell transplants for primary solid tumors and lymphoma.	Jane Koo/ Christopher E. Dandoy
Lymphoma	LY24-01	Hematopoietic cell transplantation for rare mature T-cell lymphomas.	Mehdi Hamadani/ Alex Herrera
Morbidity, Recovery and Survivorship	MRS24-01	Toxicity profile and survival of patients with body mass index >30 undergoing allogeneic stem cell transplantation.	Natalia Tijaro Ovalle/ Ann Jakubowski
Morbidity, Recovery and Survivorship	MRS24-02	Determinants of immune effector cell-associated hematotoxicity following CAR-T therapy across disease entities.	Kai Rejeski/ Roni Shouval
Non-Malignant Diseases	NM24-01	The outcomes of PTCY based GVHD prophylaxis for allogeneic stem cell transplantation in patients with severe aplastic anemia patients who lack a HLA-matched sibling donor.	Niranjan Khaire/ Lohith Gowda/ Abu-Sayeeef Mirza/ Rajat Kumar/ Brian Ball
Non-Malignant Diseases	NM24-02	Impact of somatic mutations in aplastic anemia after allogeneic stem cell transplantation	Brian Ball/ Ryotaro Nakamura
Pediatric Cancer	PC24-01	Transplantation and cellular therapy for children and young adults with down's syndrome and acute leukemia.	Lauren Appell/ Seth Rotz
Plasma Cell Disorders	MM24-01	Safety and efficacy of ciltacabtagene in patients with relapsed or refractory multiple myeloma.	Doris Hansen/ Krina Patel/ Hamza Hashmi/ Saad Usmani/ Ravi Narra/ Binod Dhakal/ Aimaz Afrough/ Larry Anderson/ Aram Bidikian/ Lohith Gowda/ Danai Dima/ Nausheen Ahmed/ Surbhi Sidana/ Sayeef Mirza/ Taiga Nishihori/ Hira Mian/ Meera Mohan/ Muhammad Faisal
Plasma Cell Disorders	MM24-02	Real-world comparison of anti-BCMA CAR T-cell therapies in relapsed or refractory multiple myeloma.	Meera Mohan/ Carolina Schinke/ Aram Bidikian/ Lohith Gowda/ Ciara Freeman/ Doris Hansen/ Supriya Gupta/ Aimaz Afrough/ Larry Anderson/ Murali Janakiram/ Scott Goldsmith/ Sairah Ahmed/ Krina Patel/ Maxwell Krem/ Nausheen Ahmed